News Novartis CEO joins board of "responsible" AI firm Anthropic In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.
News Novartis snaps up food allergy firm Excellergy for $2bn Novartis has signed its second M&A deal in the space of a week, pledging to pay up to $2 billion to acquire US food allergy drug developer Excellergy.
News Patient sues Novartis, claiming data-tracking privacy breach A cancer patient in the US has filed a class action lawsuit against Novartis in the US, claiming that the company shared her private health data.
News Novartis snaps up PI3Kα breast cancer drug in $3bn deal Novartis has agreed to buy a PI3Kα-targeting drug for breast cancer from Synnovation, a potential successor to its Piqray brand, for $2bn upfront.
News US court says pharma giants must face False Claims suit An appeals court in the US has said AbbVie, AstraZeneca, Novartis, and Sanofi must defend claims they defrauded federal and state governments.
News New biotech Atrium born out of Novartis/Avidity marriage Atrium Therapeutics has launched with $270m in funding and two preclinical siRNA candidates for rare genetic cardiomyopathies.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.